Followers | 263 |
Posts | 32941 |
Boards Moderated | 2 |
Alias Born | 01/24/2013 |
Thursday, February 04, 2021 2:22:31 PM
Clinical Stage Biotechnology Company Partners with Community Health Care Innovator
ELK CITY, Idaho, Feb. 4, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announces today the signing of a Master Sales Agreement with Community Shield LLC of Sheridan Wyoming to distribute its science-based nutraceutical line of products.
Products to be included in the Master Sales Agreement currently consists of QuadraMune™, NanoStilbene™, NeuroStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, and ProJuvenol®. Future products will be added to Master List as commercialized and provide same levels of discount.
"Execution of this sales agreement by our new Vice President of Business development Famela Ramos, is a significant milestone for us. Community Shield LLC is a company focused on developing innovative ways to deliver optimum health care to specific communities based on science and not opinions or politics, makes CSL an ideal partner," said Timothy Dixon, President and CEO of TSOI. "Since our Company is laser focused on operating as an 'innovation factory', we rely on external partnerships such as this to provide sales and marketing for our nutraceuticals, which results in a mutually beneficial relationship."
"While nutraceuticals are a multibillion-dollar market, we at Therapeutic Solutions International pride ourselves on being 'science first'. Every product that we sell is backed by laboratory data, and in some cases clinical data," said Famela Ramos, Vice President of Business Development. "We are enthusiastic to enter relationships with specialized groups who are positioned to accelerate awareness of our natural and science-based catalogue of products."
"Our ability to distribute the revolutionary products of TSOI is a key element in protecting community health. Science is taking major strides in therapeutic technologies and their importance to immune system health. TSOI is an industry-leader in developing these technologies," said Steve Scholl, Principal of Community Shield LLC.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com
Being led around by people who tell you what you want to hear, is not only dangerous, it's not much of a trading strategy.
Recent TSOI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:17:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 06:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 05:44:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:24:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 11:10:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 08:29:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM